Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
806.8 EUR | +0.52% | +4.79% | +53.26% |
06-12 | Eli Lilly Gets FDA Approval for Selpercatinib to Treat Thyroid Cancer | MT |
06-12 | Novo Nordisk, Eli Lilly's Weight-Loss Drugs Coverage Dropped by Blue Cross Blue Shield of Michigan | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With an expected P/E ratio at 64.87 and 46.69 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+53.26% | 781B | - | ||
-7.23% | 350B | C+ | ||
+19.43% | 330B | B- | ||
+7.18% | 293B | C+ | ||
+17.30% | 248B | B+ | ||
-0.08% | 221B | A+ | ||
+11.42% | 217B | B- | ||
+4.53% | 162B | C+ | ||
-3.92% | 157B | C+ | ||
-1.19% | 121B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LLY Stock
- LLY Stock
- Ratings Eli Lilly and Company